Schizophrenia.com
Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia
News
firemonkey
July 16, 2021, 6:44am
1
7 Likes
Related topics
Topic
Replies
Views
Activity
Novel GPR139 agonist evaluated in schizophrenia mouse model
News
5
258
November 29, 2023
Redirecting the revolution: new developments in drug development for psychiatry
News
3
371
September 24, 2019
Pilot study for TAK-041 in motivational anhedonia
News
12
1505
May 24, 2022
ATP-binding cassette transporter 13 mRNA expression level in schizophrenia patients
News
0
189
December 14, 2020
Arena Pharma (ARNA), Boehringer Ingelheim to Collaborate on Research in Schizophrenia
News
0
602
January 13, 2016